Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 4/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5309587 | 0.86 | HDAC3 (0.57) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL2882513 | 0.84 | HDAC3 (0.56) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5106183 | 0.84 | HDAC3 (0.56) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL3621455 | 0.84 | ESR1 (0.56) | ALDH1A1KMT2AMEN1NPC1MAPT | |
| SCHEMBL12265856 | 0.83 | KMT2A (0.51) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL6286010 | 0.82 | HDAC3 (0.56) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1376745 | 0.82 | L3MBTL1 (0.58) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL7059758 | 0.82 | KMT2A (0.63) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL6284563 | 0.82 | HDAC3 (0.54) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL3830886 | 0.80 | HDAC3 (0.61) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2502918-B1 | Pyridazinone Derivatives | CEPHALON INC (US) | 2015-03-25 | — | — | EP | disclosed |
| US-20140142088-A1 | PYRIDAZINONE DERIVATIVES | CEPHALON, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-8673916-B2 | Methods of treating disorders mediated by histamine H3 receptors using pyridazinone derivatives | CEPHALON, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8586588-B2 | Aryl pyridazinone derivatives and their use as H3 receptor ligands | CEPHALON, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2069312-B1 | PYRIDIZINONE DERIVATIVES | CEPHALON INC (US) | 2012-11-07 | — | — | EP | disclosed |
| EP-2502918-A1 | Pyridizinone Derivatives | Cephalon, Inc. (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2492263-A1 | Pyridizinone Derivatives | Cephalon, Inc. (US) | 2012-08-29 | — | — | EP | disclosed |
| US-8247414-B2 | Pyridizinone derivatives and the use thereof as H3 inhibitors | CEPHALON, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8207168-B2 | Pyridazinone derivatives | CEPHALON, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20110288075-A1 | Pyridazinone Derivatives | CEPHALON, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20100280007-A1 | Pyridazinone Derivatives | CEPHALON, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100273779-A1 | Pyridazinone Derivatives | CEPHALON, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| EP-2069312-A2 | PYRIDIZINONE DERIVATIVES | Cephalon, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008013838-A2 | PYRIDIZINONE DERIVATIVES | CEPHALON, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| US-20080027041-A1 | Pyridizinone derivatives | CEPHALON, INC. (US) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027041-A1 | Pyridizinone derivatives | H1-5, H1-3, H1-4 | HDAC3 24/4885HDAC4 39/4885HDAC1 22/4885 |
| US-20100280007-A1 | Pyridazinone Derivatives | HRH3, HNMT, HRH4 | HDAC3 484/4885HDAC4 211/4885HDAC1 395/4885 |
| US-20110288075-A1 | Pyridazinone Derivatives | HRH3, HNMT, HRH4 | HDAC3 411/4885HDAC4 177/4885HDAC1 346/4885 |
| US-20140142088-A1 | PYRIDAZINONE DERIVATIVES | HRH3, HNMT, HRH4 | HDAC3 368/4885HDAC4 175/4885HDAC1 309/4885 |
| US-20100273779-A1 | Pyridazinone Derivatives | HRH3, HNMT, HRH4 | HDAC3 484/4885HDAC4 211/4885HDAC1 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.